{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-22-000444","form_type":"8-K","ticker":"ARTL","cik":"0001621221","company_name":"ARTELO BIOSCIENCES, INC.","filed_at":"2022-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.416548+00:00","generated_at":"2026-06-26T23:59:02.776340+00:00","sec_items":["5.02","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Artelo Bio CAReS trial on track; board approves 2022 goals, cuts quorum to 35%","bullets":["CEO Gorgas eligible for 2022 bonus based on goals: clinical (40%), pre-clinical (35%), financial (25%).","Bylaws amended to reduce shareholder quorum requirement to 35%.","CAReS Phase 1 enrollment for ART27.13 expected to complete by end of Q1 2022.","Phase 1 results to inform dose selection within ~6 weeks of last patient; optional fourth cohort possible.","Company currently sees no significant COVID-19 impact on trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-22-000444","json":"https://secwatch.observer/filing/0001640334-22-000444.json","markdown":"https://secwatch.observer/filing/0001640334-22-000444.md","text":"https://secwatch.observer/filing/0001640334-22-000444.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1621221/000164033422000444/0001640334-22-000444-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1621221/000164033422000444/artl_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T23:59:02.776340+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}